Close



Feb 27, 2024 07:05AM
Jan 8, 2024 09:03AM
Jan 8, 2024 09:00AM
Dec 11, 2023 07:04AM
Dec 11, 2023 07:00AM
Nov 1, 2023 07:05AM
Oct 2, 2023 07:00AM Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
Jul 31, 2023 07:00AM
May 4, 2023 04:05PM
Feb 21, 2023 04:13PM
Feb 21, 2023 04:13PM
Nov 18, 2022 12:25PM
Nov 18, 2022 07:01AM
Nov 18, 2022 07:00AM Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
Nov 18, 2022 07:00AM
Nov 7, 2022 04:05PM
Nov 7, 2022 04:05PM
Nov 3, 2022 09:05AM
Nov 3, 2022 09:05AM
Aug 9, 2022 04:01AM
Aug 9, 2022 04:00AM UPDATE: Apellis Pharmaceuticals (APLS) PT Raised to $52 at Credit Suisse
Aug 8, 2022 04:05PM
Aug 8, 2022 04:05PM
Jul 19, 2022 07:04AM
Jul 19, 2022 07:00AM
Jul 19, 2022 07:00AM
Jun 10, 2022 05:34AM
Jun 10, 2022 03:00AM Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
Jun 10, 2022 03:00AM
May 12, 2022 11:05AM
May 12, 2022 11:05AM
May 5, 2022 06:49AM
May 4, 2022 04:05PM
May 4, 2022 04:05PM
May 3, 2022 07:00AM Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
May 3, 2022 07:00AM
Feb 28, 2022 04:05PM
Feb 28, 2022 04:05PM
Dec 13, 2021 11:45AM
Dec 13, 2021 11:45AM
Nov 8, 2021 04:01PM
Nov 8, 2021 04:01PM Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
Nov 4, 2021 09:17AM
Nov 4, 2021 09:17AM
Oct 15, 2021 07:17AM
Oct 15, 2021 07:17AM
Oct 15, 2021 07:17AM
Aug 9, 2021 04:01PM
Aug 9, 2021 04:01PM Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
Jul 6, 2021 08:00AM

13,127 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All